ArticleTheranostics2022
Interleukin-37 exacerbates experimental colitis in an intestinal microbiome-dependent fashion.
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Characteristics of T-Cells Expressing IL-37 and Its Receptors in Inflammatory Bowel Disease.International journal of molecular sciences · 2026Article
- Local Peritoneal Cytokine Response IL-1β, IL-6, TNF-α in a Standardized Neonatal Rat Model of Necrotizing Enterocolitis.International journal of molecular sciences · 2026Article
- Programmed Probiotics Generate Interleukin-37b-Bearing Nanovesicles In Situ for Precision Immunomodulation in Colitis.Research (Washington, D.C.) · 2026Article
- Major bioactive metabolites derived fromFrontiers in pharmacology · 2026Review
- The complex role of IL-37 in cancer pathogenesis: exploring its influence on hallmarks of cancer.Frontiers in immunology · 2026Review
- Suppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The role of interleukin-37 and interleukin-38 in the development and remission of autism spectrum disorder: a comprehensive review of neuroinflammatory mechanisms and potential therapeutic implications.Frontiers in immunology · 2025Review
- Gut microbiota as a key regulator in endometriosis: mechanisms, therapeutic opportunities, and future perspectives.Frontiers in cellular and infection microbiology · 2025Review
- Living Conditions Alter Ketogenic Diet-induced Metabolic Consequences in Mice through Modulating Gut Microbiota.Phenomics (Cham, Switzerland) · 2024Article
- Strategies for targeting cytokines in inflammatory bowel disease.Nature reviews. Immunology · 2024Review
- The role of IL-37 in gastrointestinal diseases.Frontiers in immunology · 2024Review
- Unraveling the microbial puzzle: exploring the intricate role of gut microbiota in endometriosis pathogenesis.Frontiers in cellular and infection microbiology · 2024Review
- IL‑37 suppresses macrophage ferroptosis to attenuate diabetic atherosclerosis via the NRF2 pathway.Experimental and therapeutic medicine · 2023Article
- Network Pharmacology Study of Bioactive Components and Molecular Mechanisms of the Glycoside Fraction fromDrug design, development and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.